1. Home
  2. ENTO vs FAMI Comparison

ENTO vs FAMI Comparison

Compare ENTO & FAMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTO
  • FAMI
  • Stock Information
  • Founded
  • ENTO 2014
  • FAMI 2015
  • Country
  • ENTO United States
  • FAMI China
  • Employees
  • ENTO N/A
  • FAMI N/A
  • Industry
  • ENTO Biotechnology: Pharmaceutical Preparations
  • FAMI Packaged Foods
  • Sector
  • ENTO Health Care
  • FAMI Consumer Staples
  • Exchange
  • ENTO Nasdaq
  • FAMI Nasdaq
  • Market Cap
  • ENTO 1.9M
  • FAMI 2.2M
  • IPO Year
  • ENTO 2016
  • FAMI 2018
  • Fundamental
  • Price
  • ENTO $0.48
  • FAMI $1.88
  • Analyst Decision
  • ENTO
  • FAMI
  • Analyst Count
  • ENTO 0
  • FAMI 0
  • Target Price
  • ENTO N/A
  • FAMI N/A
  • AVG Volume (30 Days)
  • ENTO 1.6M
  • FAMI 23.7K
  • Earning Date
  • ENTO 05-15-2025
  • FAMI 08-08-2025
  • Dividend Yield
  • ENTO N/A
  • FAMI N/A
  • EPS Growth
  • ENTO N/A
  • FAMI N/A
  • EPS
  • ENTO N/A
  • FAMI N/A
  • Revenue
  • ENTO N/A
  • FAMI $64,131,332.00
  • Revenue This Year
  • ENTO N/A
  • FAMI N/A
  • Revenue Next Year
  • ENTO N/A
  • FAMI N/A
  • P/E Ratio
  • ENTO N/A
  • FAMI N/A
  • Revenue Growth
  • ENTO N/A
  • FAMI N/A
  • 52 Week Low
  • ENTO $0.19
  • FAMI $1.43
  • 52 Week High
  • ENTO $1.12
  • FAMI $7.44
  • Technical
  • Relative Strength Index (RSI)
  • ENTO 52.62
  • FAMI 53.20
  • Support Level
  • ENTO $0.39
  • FAMI $1.80
  • Resistance Level
  • ENTO $0.41
  • FAMI $2.17
  • Average True Range (ATR)
  • ENTO 0.06
  • FAMI 0.14
  • MACD
  • ENTO 0.00
  • FAMI 0.01
  • Stochastic Oscillator
  • ENTO 57.75
  • FAMI 44.62

About ENTO Entero Therapeutics Inc. Common Stock

Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

About FAMI Farmmi Inc.

Farmmi Inc is an investment holding company. Through its subsidiaries, it acts as a supplier of agricultural products. It is an agricultural technology enterprise focused on its supply chain platform by promoting edible mushroom products and agriculture technology. Its product offerings include tapioca, corn, red dates, shiitake mushrooms, mu er fungus, other edible fungi, and other agricultural products. Geographically, the company's products are sold in China, Southeast Asia, Japan, North America, Europe, and the Middle East under the Forasen and Farmmi brands.

Share on Social Networks: